At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 847 enrolled
Drug / intervention
Amlodipine 10 mg +2 moredrug
Likely dose
Amlodipine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy
In Brief
A Phase 3 clinical trial evaluating Amlodipine 10 mg, Aliskiren 150, and 1 other intervention for Hypertension. Completed, enrolled 847 participants across 7 sites in 7 countries.
Detailed Summary
This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients with hypertension not adequately controlled with amlodipine alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesArgentina, Germany, Norway, Poland, Slovakia, Sweden, Turkey (Türkiye)
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedOct 2008
Primary CompletionJun 2009
TodayJul 2026
First PostedOct 24, 2008
Enrollment StartOct 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.7 years ago
Interventions
Amlodipine 10 mgdrug
Amlodipine 10 mg
Aliskiren 150drug
Aliskiren/Amlodipine 150/10 mg
Amlodipine 300drug
Aliskiren/Amlodipine 300/10 mg